Patents Examined by Lynn A. Bristol
  • Patent number: 11613572
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 28, 2023
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Patent number: 11607452
    Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 21, 2023
    Assignee: NeoTX Therapeutics Ltd.
    Inventors: Asher Nathan, Michal Shahar
  • Patent number: 11590217
    Abstract: Cancer is treated via a coordinated treatment regimen that use various compounds and compositions that employ prime-boost vaccination in combination with immune modulatory treatment and biasing of an immune response towards a Th1 profile.
    Type: Grant
    Filed: April 22, 2019
    Date of Patent: February 28, 2023
    Assignee: NantCell, Inc.
    Inventors: Shahrooz Rabizadeh, Patrick Soon-Shiong
  • Patent number: 11578123
    Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The antibodies are designed for the diagnosis and/or treatment of TNF-mediated disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of the antibodies in medicine are also described.
    Type: Grant
    Filed: September 12, 2018
    Date of Patent: February 14, 2023
    Assignee: Novartis AG
    Inventors: Leonardo Borras, Tea Gunde, David Urech
  • Patent number: 11572409
    Abstract: The present invention relates to antibodies having specificity for BTN2 and uses thereof, in particular for the treatment of cancer.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: February 7, 2023
    Assignees: IMCHECK THERAPEUTICS SAS, INSERM, INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, CNRS
    Inventors: Daniel Olive, Christine Pasero
  • Patent number: 11572413
    Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: February 7, 2023
    Assignee: PRECISION BIOLOGICS, INC.
    Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
  • Patent number: 11566071
    Abstract: The presently disclosed subject matter provides antibodies that bind to GPRC5D and methods of using the same.
    Type: Grant
    Filed: December 31, 2019
    Date of Patent: January 31, 2023
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu
  • Patent number: 11560437
    Abstract: The invention relates to multispecific antibody constructs comprising Fab fragments having a particular set of mutations at the interface of the CH1 and CL domains, the mutations preventing heavy chain/light chain mispairing.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: January 24, 2023
    Assignee: BIOMUNEX PHARMACEUTICALS
    Inventors: Eugene Zhukovsky, Olivier Leger, Richard J. Morse
  • Patent number: 11555072
    Abstract: The present disclosure relates generally to immunoglobulin-related compositions such as antibodies or antigen binding fragments thereof that can bind to and neutralize the activity of A33 protein. The antibodies of the present technology are useful in methods for detecting and treating an A33-positive cancer in a subject in need thereof.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: January 17, 2023
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Zhihao Wu, Hong Xu, Nai-Kong Cheung
  • Patent number: 11555071
    Abstract: The invention provides bispecific antibodies binding to human carcinoembryonic antigen CEACAM5 and human CD47, polynucleotides encoding such bispecific antibodies and vectors and host cells comprising such polynucleotides. The invention further provides methods for selecting and producing such antibodies and methods of using such antibodies in the treatment of diseases in monotherapy as well in combination.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: January 17, 2023
    Assignee: LamKap Bio beta Ltd.
    Inventors: Vanessa Buatois, Stefano Majocchi, Klaus Strein
  • Patent number: 11555074
    Abstract: The present disclosure provides an antibody, antigen binding fragment thereof, or an antibody conjugate thereof, useful in methods for treatment or diagnosis of conditions characterized by the expression of PTGFRN. The antibodies or antigen binding fragments thereof may also be used in imaging or detecting cells that express PTGFRN.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: January 17, 2023
    Assignee: A & G Pharmaceutical, Inc.
    Inventor: Ginette Serrero
  • Patent number: 11548951
    Abstract: Antibodies and compositions against Insulin-Like Growth Factor-1 Receptor (IGF-1R) and uses thereof are provided herein and antibodies and pharmaceutical compositions that can be used in methods of treating or reducing the severity of thyroid eye disease (TED) in subjects in need thereof, including reducing proptosis and Clinical Activity Score (CAS) in said subjects, by inhibiting the activity of IGF-1R with such antibodies and compositions.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: January 10, 2023
    Assignee: VIRIDIAN THERAPEUTICS, INC.
    Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
  • Patent number: 11542301
    Abstract: The present application addresses the problem of providing an Fc-binding protein having an improved antibody separation ability. The present application also addresses the problem of providing a high-accuracy antibody separation method using an insoluble carrier having the protein immobilized thereon. The problems can be solved by: an Fc-binding protein in which at least an amino acid substitution at a specific position therein occurs and which has reduced affinity for an antibody; and an antibody separation method including allowing an equilibration buffer solution to pass through a column in which an insoluble carrier having the protein immobilized thereon is filled to equilibrate the column, adding a solution containing an antibody to cause the adsorption of the antibody onto the carrier, and eluting the antibody adsorbed on the carrier using an elution solution.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: January 3, 2023
    Assignee: TOSOH CORPORATION
    Inventors: Yosuke Terao, Yoshiharu Asaoka, Ryoko Otake, Satoshi Endo, Naoki Yamanaka, Yukie Yamamoto, Seigo Oe
  • Patent number: 11534489
    Abstract: Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and uses and methods using the same.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: December 27, 2022
    Assignee: Agency for Science, Technology and Research
    Inventors: Cheng-i Wang, Hsueh Ling Janice Oh, Siok Ping Yeo
  • Patent number: 11535674
    Abstract: The present disclosure discloses a method for expressing and preparing a bivalent bispecific antibody. In the present disclosure, each portion of a bivalent bispecific antibody and an immune hybrid protein thereof is respectively expressed in a suitable prokaryotic or eukaryotic cell system, separated and purified by high-performance affinity chromatography, and then spliced in vitro by trans-splicing reaction mediated by an intein, to prepare the bivalent specific antibody and an immune hybrid protein thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: December 27, 2022
    Assignees: SHANGHAI JIAO TONG UNIVERSITY, JECHO LABORATORIES INC., JECHO BIOPHARMACEUTICALS CO LTD.
    Inventors: Lei Han, Jianwei Zhu, Junsheng Chen, Kai Ding, Yueqing Xie, Hua Jiang, Huili Lu, Baohong Zhang, Lei Zhang
  • Patent number: 11530266
    Abstract: The object of the present invention is to provide a humanized or mouse-human chimeric anti-podoplanin antibody or an antibody fragment containing the antigen-binding region thereof, and the object is achieved by providing an isolated humanized or mouse-human chimeric anti-podoplanin antibody which comprises a predetermined amino acid sequence, or an antibody fragment containing the antigen-binding region thereof.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: December 20, 2022
    Assignee: JAPANESE FOUNDATION FOR CANCER RESEARCH
    Inventors: Nobuhiko Gyobu, Naoya Fujita, Mamoru Kakino, Ai Kawashima, Shinya Fujihara, Naoki Goda
  • Patent number: 11524998
    Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
    Type: Grant
    Filed: July 14, 2021
    Date of Patent: December 13, 2022
    Assignee: NOVARTIS AG
    Inventors: Chad Eric Bigelow, Ana Maria Carrion, James Edgar Chastain, Kirk Lee Clark, Bijan Alexandre Etemad-Gilbertson, Joy Gispati Ghosh, Shawn Michael Hanks, Nicole Haubst, Ganesh Rajan Iyer, Nina Moker, Andrew Anh Nguyen, Stephen Hedrick Poor, Yubin Qiu, Nalini Velamur Rangaswamy, Michael Stefanidakis, Engin Toksoz, Michael Zbigniew Twarog
  • Patent number: 11525009
    Abstract: Provided in the present invention is a bispecific antibody which comprises an anti-MUC1 VHH antibody fragment and an anti-CD16 VHH antibody fragment. The antibody fragment used in the present invention is a variable region sequence derived from a heavy chain camelid antibody and has a high binding affinity to the antigen. Antibody fragments recognizing MUC1 and CD16 are constructed in the same antibody molecule by the invention, so that the antibody molecule can specifically bind to MUC1 and CD16 molecules to promote the killing effect of NK cells on MUC1-positive expression cells and has an inhibiting effect on the growth of MUC1-positive tumors. Also provided is a conjugate of the bispecific antibodies, a related pharmaceutical composition and use.
    Type: Grant
    Filed: June 21, 2017
    Date of Patent: December 13, 2022
    Assignee: BENHEALTH BIOPHARMACEUTIC (SHENZHEN) CO. LTD.
    Inventors: Haoyang Yu, Zhong Wang, Zhengcheng Li
  • Patent number: 11512129
    Abstract: A TIGIT antibody, an antigen-binding fragment thereof, and a medical use thereof. The present invention relates to a murine antibody, a chimeric antibody, and a humanized antibody comprising a CDR region of the TIGIT antibody, and a pharmaceutical composition comprising the TIGIT antibody and the antigen-binding fragment thereof, and a use thereof as a medicament. In particular, the present invention also relates to a use of a humanized TIGIT antibody for preparing a medicament for the treatment of TIGIT-associated diseases or conditions.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: November 29, 2022
    Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.
    Inventors: Yayuan Fu, Zhuoxiao Cao, Qiyue Hu, Weikang Tao
  • Patent number: 11513122
    Abstract: The invention is concerned with a method of predicting response to a PD-1 axis inhibitor such as anti-PD-L1 antibody by determining the abundance of dendritic cells (DCs) in a tumor tissue sample. The abundance of DCs characterized by enhanced expressions of XCR1, IRF8, BATF3 and FLT3 predicts clinical response to the PD-L1 blockade 5 treatment.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: November 29, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Maud LĂ©a Mayoux, Andreas Roller, Wei Xu